SMN1 and proximal spinal muscular atrophy: Thus, while there are no significant differences in the levels of pro-inflammatory and anti-inflammatory cytokines or neurotrophic factors between SMA2 and SMA3 patients prior to treatment, Nusinersen appears to paradoxically trigger distinct immunological responses in milder SMA patients, which may reflect off target effects of this drug in the CNS.